FIG. 1



(A)
variable region
target-binding region
C20 alcohol
(B)
SN-38 (1)
Belotecan (2)
Exatecan (3)
9AC (4)

FIG. 2





HIPS ligation

FIG. 3




#	Time	Area	Height	Width	Area%	Symmetry
1	5.926	352.7	7.6	0.3843	3.396	0.375
2	6.795	10040.7	78.4	0.4128	42.655	1.673
3	7.118	13470.5	80	0.4653	53.949	0.588

FIG. 4




#	Time	Area	Height	Width	Area%	Symmetry
1	7.556	98.3	17.8	0.536	5.836	0
2	8.795	8055.7	321.6	0.469	94.164	0.795

FIG. 5




#	Time	Area	Height	Width	Area%	Symmetry
1	5.28	86	17	0.1507	1.715	943.165
2	7.242	2058.4	867.9	0.1498	41.733	1.711
3	7.846	4746.2	112.8	0.5878	57.064	1.205

FIG. 6




#	Time	Area	Height	Width	Area%	Symmetry
1	7.26	782.9	35.5	0.5139	4.521	0
2	8.176	16522.2	667.9	0.4128	95.479	0.76

FIG. 7




#	Time	Area	Height	Width	Area%	Symmetry
1	3.478	376.9	51.4	0.1227	3.955	1.138
2	3.674	5098.8	681.7	0.3015	53.525	0.708
3	3.945	4055.6	266	0.3413	42.520	0.726

FIG. 8




#	Time	Area	Height	Width	Area%	Symmetry
1	4.38	94.9	2	0.2667	0.927	0.591
2	5.11	33.4	3.1	0.157	0.621	0.518
3	6.623	350.1	32.9	0.468	3.383	0.699
4	7.82	2038.9	76.7	0.4667	38.648	1
5	8.06	1215.6	101.6	0.1984	32.305	0.739

FIG. 9



#	Time	Area	Height	Width	Area%	Symmetry
1	7.216	311.2	4.9	0.75	3.426	0
2	8.861	8949.5	103.8	0.903	96.574	0.968

FIG. 10



#	Time	Area	Height	Width	Area%	Symmetry
1	3.403	37.9	2.5	0.222	1.961	5610.27
2	3.985	853.6	98.3	0.2998	44.121	0
3	4.336	1043.1	56.8	0.3435	53.916	0.231

FIG. 11



Norm.
min
Time Area Height Width Area% Symmetry
1 7.745 7.8 1.9E-1 0.6769 0.853 5821.38
2 8.434 909.1 34.6 1.0388 99.147 0.961

FIG. 12





Norm.
min
Time Area Height Width Area% Symmetry
1 3.424 395.4 77 0.1205 1.848 2.529
2 3.758 9817.1 393.6 0.2736 45.893 1.581
3 4.695 7591 369.8 0.3434 35.495 1.149

FIG. 13




#	Time	Area	Height	Width	Area%	Symmetry
1	4.64	69	2.7	0.4277	1.384	0.297
2	5.48	28.5	5.6	0.3405	1.571	0.123
3	6.184	247.3	32.4	0.3178	4.964	0.269
4	7.017	4035.7	81.9	0.3821	38.481	1
5	7.974	3662.5	167	0.2458	53.396	0.719

FIG. 14




#	Time	Area	Height	Width	Area%	Symmetry
1	7.105	301.3	6.3	0.5803	4.274	24.354
2	8.387	6756.3	150.3	0.8468	95.726	6.592

FIG. 15




#	Time	Area	Height	Width	Area%	Symmetry
1	3.408	284.3	23.7	0.1978	1.602	0.78
2	3.787	16684.1	817	0.3809	96.908	0.758
3	4.188	6576.8	354.6	0.2981	37.470	0.778

FIG. 16




#	Time	Area	Height	Width	Area%	Symmetry
1	4.977	65.7	2.6	0.4295	0.946	0.53
2	5.267	102.6	4.9	0.3602	1.477	0.769
3	5.954	401.2	21	0.3389	5.774	0.474
4	7.967	1678.4	77.5	0.3608	24.155	2.512
5	7.918	4700.4	215.9	0.3628	67.648	1.747

FIG. 17



#	Time	Area	Height	Width	Area%	Symmetry
1	6.728	296.2	6.3	0.8408	3.234	0
2	7.904	10857.3	224.1	0.7927	96.766	0.524

FIG. 18



#	Time	Area	Height	Width	Area%	Symmetry
1	6.408	1028	80.3	0.2124	17.131	0.474
2	7.668	756.7	46.3	0.2784	11.967	2.035
3	8.665	4246.3	365.1	0.1976	70.901	0.6

FIG. 19



Norm.
175
150
125
100
75
50
25
0
2
4
6
8
10
12
14
16
18
20
Area: 9703.9
Area: 196.3
Time Area Height Width Area% Symmetry
1 7.968 196.3 3.4 0.739 1.986 0
2 8.469 9703.9 196.3 0.8167 98.410 0.927

FIG. 20



Norm.
350
300
250
200
150
100
50
0
1
2
3
4
5
Area: 2381.2
Area: 2383.2
Time Area Height Width Area% Symmetry
1 3.481 118.9 20.4 0.1918 2.532 60.988
2 3.974 2263.9 114.1 0.3263 47.798 1.131
3 4.122 2381.2 114.4 0.3481 50.088 0.132

FIG. 21



Norm.
min
Time Area Height Width Area% Symmetry
1 7.097 385.5 7.4 0.6369 3.645 1.899
2 8.172 7804 152.2 0.8218 96.380 0.536

FIG. 22





Norm.
min
Time Area Height Width Area% Symmetry
1 3.536 33 5.96-1 0.2431 1.452 0
2 4.234 951 22.3 0.3351 48.759 0.495
3 4.466 950.2 20.3 0.3704 49.809 0.236

FIG. 23




#	Time	Area	Height	Width	Area%	Symmetry
1	7.106	77	3.867	0.6636	1.232	0
2	8.272	7283.7	73.8	0.9429	98.768	0.907

FIG. 24




#	Time	Area	Height	Width	Area%	Symmetry
1	3.618	200.1	20.9	0.1658	2.749	2.126
2	3.957	3170.7	196.2	0.2117	43.576	1.767
3	4.087	3713.5	136.7	0.3803	51.014	0

FIG. 25




#	Time	Area	Height	Width	Area%	Symmetry
1	6.95	620	18.7	0.488	5.283	0.977
2	8.036	11127	238.1	0.7810	94.717	0.513

FIG. 26




#	Time	Area	Height	Width	Area%	Symmetry
1	3.654	61.2	4.1	0.2677	0.998	1.047
2	4.017	4661.6	238.9	0.3494	54.082	0.453
3	4.289	3916.5	191.3	0.3403	45.313	0

FIG. 27




#	Time	Area	Height	Width	Area%	Symmetry
1	6.628	264.4	24.1	0.2546	0.255	0
2	7.258	10375.8	951.9	0.7361	99.745	0.462

FIG. 28




#	Time	Area	Height	Width	Area%	Symmetry
1	6.464	1979.6	171.8	0.1896	16.604	0.704
2	6.612	4979.1	356.8	0.212	49.264	0
3	6.764	3058.2	240.3	0.2126	30.133	0.35

FIG. 29




#	Time	Area	Height	Width	Area%	Symmetry
1	6.91	240.1	8.9	0.8196	1.868	0
2	7.999	12610.2	386.4	0.7652	98.132	0.495

FIG. 30




#	Time	Area	Height	Width	Area%	Symmetry
1	3.998	65.4	7.3	0.1042	1.256	1.014
2	4.673	2736.2	138.1	0.3256	75.779	0.208
3	4.228	835.1	69.1	0.2053	22.965	0.681

FIG. 31



#	Time	Area	Height	Width	Area%	Symmetry
1	7.022	933.7	30.7	0.6751	5.014	1.014
2	8.193	17692.7	135	0.9697	94.986	0.458

FIG. 32



#	Time	Area	Height	Width	Area%	Symmetry
1	3.758	55.4	12.1	0.0726	1.089	218.98
2	3.87	3758.2	201	0.31	76.757	5
3	4.441	1065.4	83.8	0.2007	22.574	0.792

FIG. 33



mAU
min
Time Area Height Width Area% Symmetry
1 2.458 188.9 4.6 0.6422 2.168 1.069
2 5.307 6413.6 140.8 0.9478 97.832 0.671

FIG. 34



mAU
min
Time Area Height Width Area% Symmetry
1 3.403 80.7 24.1 0.6557 1.803 853.924
2 3.736 3381.6 172.5 0.3261 75.598 0.240
3 4.26 1015.8 78.6 0.2141 22.699 0.635

FIG. 35



Norm.
min
Time Area Height Width Area% Symmetry
1 8.037 604.3 14.5 0.7615 8.218 1.08
2 8.01 7435.9 129.4 0.9523 91.782 0.49

FIG. 36





Norm.
min
Time Area Height Width Area% Symmetry
1 2.756 75.7 6.8 0.1856 0.962 2.065.03
2 3.32 5996.4 281.4 0.2499 74.893 0.139
3 4.468 1917.4 104.5 0.3121 24.654 0.457

FIG. 37




#	Time	Area	Height	Width	Area%	Symmetry
1	6.411	748.0	16.2	0.772	6.006	0
2	7.495	11744.7	223.6	0.8748	94.000	0.447

FIG. 38




#	Time	Area	Height	Width	Area%	Symmetry
1	6.393	2572.3	274.9	0.2019	68.496	0.477
2	7.478	998.7	43.6	0.367	18.402	0.397
3	8.431	603.3	36	0.2478	13.102	0.637

FIG. 39




#	Time	Area	Height	Width	Area%	Symmetry
1	7.215	198.2	2.5	0.7864	1.890	0
2	7.746	3572.7	149.4	0.8530	98.110	0.37

FIG. 40




#	Time	Area	Height	Width	Area%	Symmetry
1	6.864	308.8	15.5	0.3293	3.096	0.404
2	6.921	3038.8	111.2	0.3439	30.719	0.511
3	7.006	7258.8	110.4	0.4123	42.184	0.291

FIG. 41



#	Time	Area	Height	Width	Area%	Symmetry
1	7.48	1064.5	32.3	0.5289	11.182	0.648
2	8.405	8479.5	312.5	0.4452	88.837	0.615

FIG. 42



#	Time	Area	Height	Width	Area%	Symmetry
1	6.727	76.4	7.4	0.1668	0.842	4852.83
2	7.284	4131	168.3	0.4185	45.744	5.585
3	7.446	4835	172.1	0.4609	53.414	0.282

FIG. 43



Peak: 1154.3
Peak: 455.4
Time Area Height Width Area% Symmetry
1 2.189 455.4 72.9 0.4729 3.295 0.946
2 8.586 13895.1 502 0.3946 96.757 0.795

FIG. 44





Peak: 3844.02
Peak: 557.8
Time Area Height Width Area% Symmetry
1 5.93 96.3 6.9 0.228 2.141 0.893
2 6.381 3844.5 408.7 0.4655 85.478 0.549
3 7.194 605.3 44.9 0.6275 13.381 0.75

FIG. 45




#	Time	Area	Height	Width	Area%	Symmetry
1	7.96	2226	61.7	0.6517	21.288	0.936
2	8.685	8238.2	364.5	0.4661	78.711	0.776

FIG. 46




#	Time	Area	Height	Width	Area%	Symmetry
1	6.493	30.4	3.5	0.297	1.254	0
2	6.987	5578.7	168.7	0.5495	76.852	0.222
3	7.985	2067.1	81	0.3775	27.984	0.361

FIG. 47




#	Time	Area	Height	Width	Area%	Symmetry
1	7.121	1888.3	49.3	0.5836	16.775	1.082
2	8.191	9285	355.5	0.4724	84.675	0.752

FIG. 48




#	Time	Area	Height	Width	Area%	Symmetry
1	3.424	75.9	11.3	0.1118	0.557	1.601
2	3.805	1784.8	167.9	0.1771	13.102	1.253
3	4.237	11782.6	628.6	0.3114	86.340	0.595

FIG. 49




#	Time	Area	Height	Width	Area%	Symmetry
1	5.184	19.1	1.4	0.1758	0.392	0.343
2	5.405	27.2	3.4	0.1321	0.548	0.394
3	5.671	38.5	2.8	0.2119	0.461	0.508
4	7.804	3604.3	160.8	0.3737	48.471	5.853
5	7.988	4155.3	207.5	0.2728	52.996	6.674

FIG. 50




#	Time	Area	Height	Width	Area%	Symmetry
1	7.109	315.3	6.7	0.2958	3.635	0
2	8.197	8386.6	272.6	0.8053	96.365	6.497

FIG. 51




#	Time	Area	Height	Width	Area%	Symmetry
1	3.799	3021.8	38.1	0.1353	3.645	0
2	4.078	19644.6	81.6	0.240	23.434	2288.65
3	4.403	57232.4	394.8	0.2368	72.921	0.923

FIG. 52




#	Time	Area	Height	Width	Area%	Symmetry
1	2.232	38.6	1.2	0.5498	2.072	0
2	8.398	2783.2	82.6	0.5026	97.928	6.514

FIG. 53



#	Time	Area	Height	Width	Area%	Symmetry
1	3.813	284.3	24.2	0.3027	2.882	5284.28
2	4.024	1288.6	113.4	0.1784	11.958	1.341
3	4.320	8664.8	474.8	0.3051	85.160	0.564

FIG. 54



#	Time	Area	Height	Width	Area%	Symmetry
1	4.625	96.3	7.2	0.1489	1.057	0.242
2	5.565	93.9	5.1	0.3661	0.716	5.669
3	6.18	130.8	6.2	0.2212	2.788	0.579
4	7.771	1781.8	98.3	0.2862	37.369	0
5	7.805	2777.5	157.4	0.2345	57.935	0.647

FIG. 55



Norm.
min
Time Area Height Width Area% Symmetry
1 6.779 141.1 21.1 0.7525 2.118 0
2 8.084 6947.3 127.9 0.775 97.882 0.981

FIG. 56





Norm.
min
Time Area Height Width Area% Symmetry
1 3.689 209.1 31.5 0.2339 1.823 0
2 5.169 1937 173.4 0.1862 11.807 1.529
3 5.494 14186.1 755.3 0.3232 86.369 0.465

FIG. 57




#	Time	Area	Height	Width	Area%	Symmetry
1	6.864	388.3	4.3	0.7648	3.815	0
2	7.786	9892.2	225.8	0.7164	97.185	0.466

FIG. 58




#	Time	Area	Height	Width	Area%	Symmetry
1	6.433	544.3	71.1	0.1775	7.407	0.357
2	7.789	4901.3	88.8	0.2634	20.431	0
3	7.991	2302.7	455.1	0.1864	72.162	0.586

FIG. 59




#	Time	Area	Height	Width	Area%	Symmetry
1	7.297	814.5	2	6.67	0.841	0
2	7.938	96026.3	238.3	0.7235	99.159	0.472

FIG. 60




#	Time	Area	Height	Width	Area%	Symmetry
1	6.249	155	2.7	0.5541	2.519	0
2	6.578	5513.9	66.1	0.1362	24.542	0
3	8.387	4986.6	155.5	0.481	72.944	0.262

FIG. 61




#	Time	Area	Height	Width	Area%	Symmetry
1	7.045	1123.3	8.7	0.8827	1.777	0
2	9.072	6481.2	190.5	0.5446	98.223	0.965

FIG. 62




#	Time	Area	Height	Width	Area%	Symmetry
1	2.708	90.4	2.4	0.3258	19.645	0
2	3.87	281.9	7	0.496	36.594	1.321
3	9.272	99.6	4	0.3713	27.857	0.801

FIG. 63




#	Time	Area	Height	Width	Area%	Symmetry
1	4.961	665.7	32.2	0.3561	5.009	0.56
2	6.042	707.8	37.8	0.4413	5.326	0.69
3	7.197	11951.6	480.4	0.373	89.966	1.028

FIG. 64




#	Time	Area	Height	Width	Area%	Symmetry
1	6.054	565.5	25.8	0.5046	4.407	0.753
2	7.942	12276.7	384.5	0.5321	95.593	0.86

FIG. 65




#	Time	Area	Height	Width	Area%	Symmetry
1	6.421	88.8	26.2	0.2448	5.875	0.725
2	7.564	575	35.5	0.2781	38.249	0
3	7.833	902.1	272.1	0.3648	59.877	0.776

FIG. 66




#	Time	Area	Height	Width	Area%	Symmetry
1	7.08	90.8	7.2	0.5674	0.727	0
2	8.229	6291.6	187.3	0.5687	99.228	0.563

FIG. 67




#	Time	Area	Height	Width	Area%	Symmetry
1	6.309	231.7	9.6	0.402	2.631	1.423
2	7.718	2458.5	117.1	0.343	27.898	0
3	7.877	6165.8	258.6	0.4506	70.001	0.342

FIG. 68



#	Time	Area	Height	Width	Area%	Symmetry
1	7.071	406.9	21.8	0.4121	3.324	0
2	8.024	11774.9	544.9	0.3579	96.676	0.545

FIG. 69



#	Time	Area	Height	Width	Area%	Symmetry
1	7.345	286.3	18.4	0.239	46.276	2.082
2	8.142	140.5	42.1	0.4362	36.705	0
3	8.384	1365.5	62.5	0.3725	50.035	0.467

FIG. 70




FIG. 71



Sk-Br-3 Breast Cancer Cells
% Viability
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentration (nM)
Free Belotecan
Free SN-38
Free Dxd

FIG. 72



Granta NHL Cells
% Viability
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentration (nM)
Free Belotecan
Free SN-38
Free Dxd

FIG. 73



MDA-MB-468 Breast Cancer Cells
% Viability
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentration (nM)
Free Belotecan
Free SN-38
Free Dxd

FIG. 74



MDA-PCa-2b Prostate Cancer Cells
% Viability
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentration (nM)
Free Belotecan
Free SN-38
Free Dxd

FIG. 75



MDA-MB-468 Breast Cancer Cells, TROP-2+
Viability %
150
100
50
0
0.01
1
100
10000
Drug concentration (nM)
TROP-2 Targeted ADC; DAR 6.99
Isotype ADC; DAR 6.84
Free Belotecan

FIG. 76



NCI-N87 Gastric Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
1
100
10000
Drug concentration (nM)
HER2 Targeted ADC DAR 6.7
Isotype ADC DAR 6.8
Free Belotecan

FIG. 77



SU-DHL-1 ALCL Cells, CD25+
Viability %
150
100
50
0
0.01
1
100
10000
Drug concentration (nM)
CD25 Targeted ADC, DAR 6.9
Isotype ADC, DAR 6.8
Free Belotecan

FIG. 78



BxPC-3 Pancreatic Cancer Cells, TROP-2+
Viability %
150
100
50
0
0.01
1
100
10000
Drug concentration (nM)
TROP-2 Targeted ADC, DAR 6.99
Isotype ADC, DAR 6.84
Free Belotecan

FIG. 79




NCI-N87 Gastric Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentration (nM)
Enhertu; DAR 7.82
HER2-Targeted ADC; DAR 4.9
Free Dxd
Free Belotecan

FIG. 80


Sk-Br-3 Breast Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentration (nM)
HER2-Targeted ADC; DAR 4.9
Free Belotecan
Enhertu; DAR 7.82
Free Dxd



Total Antibody
Detect with anti-human Fc
TMB
HRP
Capture with antigen or anti-human IgG
Total ADC
Detect with anti-mouse IgG1
TMB
HRP
Use mouse anti-payload primary
Capture with antigen or anti-human Fab

FIG. 81



Total Antibody
100
10
1
0.1
0.01
ug/mL
0
5
10
15
Days Post Dose

FIG. 82



Total Antibody
Total ADC
100
10
1
0.1
0.01
ug/mL
0
5
10
15
Days Post Dose

FIG. 83



100
10
1
0.1
0.01
ug/mL
0
5
10
15
Days Post Dose
Total Antibody
Total ADC

FIG. 84



100
10
1
0.1
0.01
ug/mL
0
5
10
15
Days Post Dose
Total Antibody
Total ADC

FIG. 85



Mean tumor volume (mm3)
2000
1750
1500
1250
1000
750
500
250
0
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90
Days
Vehicle
Trodelvy; 10 mg/kg (d0, 7, 21, 28)
Conjugate 3485; 6 mg/kg (d0, 21)
DS-1062; 6 mg/kg (d0, 21)

FIG. 86



1000
800
600
400
200
0
Mean tumor volume (mm3)
0
10
20
30
Days
Vehicle
DS-1062, 3 mg/kg
Conjugate 3485, 3 mg/kg
Conjugate 3789, 3 mg/kg
Conjugate 3790, 3 mg/kg

FIG. 87



Mean tumor volume (mm3)
1500
1000
500
0
0
10
20
30
40
Days
Vehicle
Compound 65 Nectin-4 Conjugate; DAR 6.8
MC-GGFG-Dxd Nectin-4 Conjugate; DAR 3.7

FIG. 88



MDA-MB-468 Breast Cancer Cells, Trop-2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Drug concentation (nM)
Compound 165 TROP-2 Conjugate; DAR 3.41
Compound 65 TROP-2 Conjugate; DAR 4.92
Compound 175 TROP-2 Conjugate; DAR 1.18
Compound 165 Isotype Conjugate; DAR 3.67
Compound 65 Isotype Conjugate; DAR 5.04
Compound 175 Isotype Conjugate; DAR 5.08
Compound 1
Compound 2

FIG. 89



BxPC-3 Pancreatic Cancer Cells, TROP-2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Conc Drug nM
Compound 165 TROP-2 Conjugate; DAR 3.41
Compound 65 TROP-2 Conjugate; DAR 4.92
Compound 175 TROP-2 Conjugate; DAR 1.18
Compound 165 Isotype Conjugate; DAR 3.67
Compound 65 Isotype Conjugate, DAR 5.04
Compound 175 Isotype Conjugate; DAR 5.08
Compound 1
Compound 2

FIG. 90



SK-BR-3 Breast Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Conc Drug nM
Compound 65 HER2 Conjugate; DAR 4.9
Compound 67 HER2 Conjugate; DAR 3.92
Compound 73 HER2 Conjugate; DAR 5.41
Compound 65 Isotype Conjugate; DAR 4.5
Compound 67 Isotype Conjugate; DAR 4.39
Compound 73 Isotype Conjugate; DAR 4.39
Compound 2

FIG. 91



NCI-N87 Gastric Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Conc Drug nM
Compound 65 HER2 Conjugate; DAR 4.9
Compound 67 HER2 Conjugate; DAR 3.92
Compound 73 HER2 Conjugate; DAR 5.41
Compound 65 Isotype Conjugate; DAR 4.5
Compound 67 Isotype Conjugate; DAR 4.39
Compound 73 Isotype Conjugate; DAR 4.39
Compound 2

FIG. 92



MDA-MB-468 Breast Cancer Cells, Trop-2+
Viability %
150
100
50
0
0.01
1
100
10000
Conc Drug nM
Compound 65 TROP-2 Conjugate; DAR 4.92
Compound 80 TROP-2 Conjugate; DAR 6.19
Compound 65 Isotype Conjugate; DAR 4.5
Compound 80 Isotype Conjugate; DAR 5.05
Compound 2

FIG. 93



BxPC-3 Pancreatic Cancer Cells, TROP-2+
Viability %
150
100
50
0
0.01
1
100
10000
Conc Drug nM
Compound 65 TROP-2 Conjugate; DAR 4.92
Compound 80 TROP-2 Conjugate; DAR 6.19
Compound 65 Isotype Conjugate; DAR 4.5
Compound 80 Isotype Conjugate; DAR 5.05
Compound 2

FIG. 94



NCI-N87 Gastric Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
1
100
10000
Conc Drug nM
Compound 99 HER2 Conjugate; DAR 4.89
Compound 103 HER2 Conjugate; DAR 6.56
Compound 110 HER2 Conjugate; DAR 6.1
Compound 99 Isotype Conjugate; DAR 3.07
Compound 103 Isotype Conjugate; DAR 4.53
Compound 110 Isotype Conjugate; DAR 5.66
Compound 2

FIG. 95



SK-BR-3 Breast Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
1
100
10000
Conc Drug nM
Compound 65 HER2 Conjugate; DAR 4.9
Compound 86 HER2 Conjugate; DAR 5.9
Compound 92 HER2 Conjugate; DAR 5.13
Compound 65 Isotype Conjugate; DAR 6.78
Compound 86 Isotype Conjugate; DAR 5.46
Compound 92 Isotype Conjugate; DAR 1.58
Compound 2

FIG. 96



MDA-MB-468 Breast Cancer Cells, Trop-2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Conc Drug nM
Compound 65 TROP-2 Conjugate; DAR 4.71
Trodelvy
Compound 65 Isotype Conjugate; DAR 4.5
CL2A-SN38 Isotype Conjugate; DAR 3.16
Compound 1
Compound 2

FIG. 97



NCI-N87 Gastric Cancer Cells, HER2+
Viability %
150
100
50
0
0.01
0.1
1
10
100
1000
Conc Drug nM
Compound 65 HER2 Conjugate; DAR 4.9
Enhertu
Compound 65 Isotype Conjugate; DAR 4.5
MC-GGFG-Dxd Isotype Conjugate; DAR 6.9
Compound 2

FIG. 98



MDA-MB-468 Breast Cancer Cells, Trop-2+
Viability %
150
100
50
0
0.01
1
100
10000
Conc Drug nM
Compound 65 TROP-2 Conjugate; DAR 3.66
Compound 113 TROP-2 Conjugate; DAR 6.41
Compound 65 Isotype Conjugate; DAR 6.67
Compound 113 Isotype Conjugate; DAR 6.39
Compound 2

FIG. 99




FIG. 100




FIG. 101




FIG. 102




FIG. 103




FIG. 104




FIG. 105




FIG. 106




FIG. 107




FIG. 108






FIG. 109




#	Time	Area	Height	Width	Area%	Symmetry
1	6.5	36.1	14.7	0.111	1.303	0.678
2	6.901	36.5	3.8	0.1621	1.309	0.467
3	7.29	257.3	28.1	0.227	4.798	0
4	8.027	2015	173.4	0.2989	91.052	0.278
5	8.157	3698	260.7	0.2531	93.591	0.417

FIG. 110




#	Time	Area	Height	Width	Area%	Symmetry
1	6.932	128.1	3.8	0.5034	1.848	0
2	7.827	6880.1	382.4	0.5987	98.152	0.962

FIG. 111



#	Time	Area	Height	Width	Area%	Symmetry
1	3.788	83.4	3.6	0.3688	0.464	0.363
2	4.380	80.2	2.7	0.3671	0.711	0
3	5.281	462.3	17.2	0.4486	4.029	0.617
4	6.951	2961.4	107.1	0.3726	21.950	0
5	7.714	8465.4	340.6	0.4136	73.598	0.795

FIG. 112



#	Time	Area	Height	Width	Area%	Symmetry
1	6.439	280.1	8.7	0.5352	2.832	0
2	7.363	9559.8	298.3	0.5435	97.168	0.498

FIG. 113




FIG. 114




FIG. 115




FIG. 116




FIG. 117




FIG. 118




FIG. 119




FIG. 120




FIG. 121




FIG. 122




FIG. 123




FIG. 124




FIG. 125




FIG. 126




FIG. 127




FIG. 128




FIG. 129




FIG. 130




FIG. 131




FIG. 132




FIG. 133




FIG. 134




FIG. 135




FIG. 136




FIG. 137




FIG. 138




FIG. 139




FIG. 140




FIG. 141




FIG. 142




FIG. 143




FIG. 144